Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.

CTX | WAR

Overview

Corporate Details

ISIN(s):
PLCPTRT00014 (+1 more)
LEI:
259400JHH1S2I2S4O735
Country:
Poland
Address:
Wrocław Duńska 11, 54-427 Wrocław
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapeutics using Targeted Protein Degradation (TPD) technology. The company focuses on creating breakthrough, first-in-class treatments for high unmet medical needs, particularly in oncology and autoimmune diseases. Its core is the proprietary Optigrade™ drug discovery platform, which leverages multidisciplinary expertise in protein engineering, structural biology, and molecular modelling. This integrated approach enables the company to address previously "undruggable" molecular targets, accelerating the development of drug candidates with the potential to significantly impact patient outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-27 13:41
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających na Nadzwyczajnym Walnym Zgromadzeniu Spółki …
Polish 2.0 KB
2025-10-24 18:29
Regulatory News Service
Zawarcie umowy z Europejską Radą ds. Innowacji i Agencją Wykonawczą ds. MŚP (EI…
Polish 1.3 KB
2025-10-22 17:51
Post-Annual General Meeting Information
treść uchwał
Polish 465.8 KB
2025-10-22 17:51
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie 22 października 20…
Polish 1.2 KB
2025-10-15 15:25
Post-Annual General Meeting Information
projekt uchwały
Polish 167.2 KB
2025-10-15 15:25
Pre-Annual General Meeting Information
Zgłoszenie przez Akcjonariusza projektu uchwały w sprawie objętej porządkiem ob…
Polish 1.1 KB
2025-10-14 18:11
Share Issue/Capital Change
Zakończenie subskrypcji akcji serii W emitowanych w związku z realizacją progra…
Polish 4.1 KB
2025-09-30 13:20
Director's Dealing
załącznik do raportu
Polish 4.3 KB
2025-09-30 13:20
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 398 bytes
2025-09-30 13:10
Director's Dealing
Załącznik do raportu
Polish 4.3 KB
2025-09-30 13:10
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 566 bytes
2025-09-30 12:53
Director's Dealing
Załącznik do raportu
Polish 4.3 KB
2025-09-30 12:53
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 543 bytes
2025-09-29 16:32
Director's Dealing
Załącznik do raportu
Polish 4.4 KB
2025-09-29 16:32
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 653 bytes

Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Captor Therapeutics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan 4978
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan 4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan 9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom RGP
ROXX, Inc. Logo
HR tech platform connecting non-desk job seekers with full-time roles using AI and vetting tools.
Japan 241A
SAFTEC CO.,LTD. Logo
Rents and sells safety equipment for construction, from basic supplies to AI/IoT solutions.
Japan 7464
Saniona Logo
Develops ion channel medicines for rare neurological diseases and epilepsy.
Denmark SANION
SBI Leasing Services Co.,Ltd. Logo
Structures Japanese Operating Leases for aircraft & ships for corporate investors.
Japan 5834
Sensorion Logo
Developing gene therapies and small molecules to restore, treat, and prevent hearing loss.
France ALSEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.